The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KMTS | N/A | N/A | N/A | +28% |
| S&P | +18.37% | +110.18% | +16.02% | +20% |
Kestra Medical Technologies Ltd. operates as a commercial-stage, wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company was founded by Brian Webster and Phillip D. Foshee in 2014 and is headquartered in Kirkland, WA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $19.37M | 51.5% |
| Gross Profit | $8.85M | 110.7% |
| Gross Margin | 45.69% | 12.8% |
| Market Cap | $847.25M | 0.0% |
| Market Cap / Employee | $2.57M | 0.0% |
| Employees | 330 | 0.0% |
| Net Income | -$25.83M | -27.1% |
| EBITDA | -$26.85M | -67.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $201.21M | 0.0% |
| Accounts Receivable | $9.25M | 0.0% |
| Inventory | 6.8 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.55M | 0.0% |
| Short Term Debt | $0.04M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -65.19% | 0.0% |
| Return On Invested Capital | -1772.90% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34.54M | -40.7% |
| Operating Free Cash Flow | -$26.27M | -50.1% |
| Metric | Q2 2025 | Q3 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Book | -4.51 | 4.12 | - | ||
| Price to Sales | 20.65 | 12.75 | - | ||
| Price to Tangible Book Value | -4.51 | 4.12 | - | ||
| Enterprise Value to EBITDA | -22.47 | -25.69 | - | ||
| Return on Equity | -130.4% | - | |||
| Total Debt | $46.10M | $46.61M | $44.31M | $44.59M | -1.28% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
